Stabilization of endogenous Nrf2 by minocycline protects against Nlrp3-inflammasome induced diabetic nephropathy

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Shahzad, Khurrum ^a,b   Bock, Fabian ^a,c   Al Dabet, Moh'D Mohanad ^a   Gadi, Ihsan ^a   Nazir, Sumra ^a   Wang, Hongjie ^a,d   Kohli, Shrey ^a   Ranjan, Satish ^a   Mertens, Peter R ^a   Nawroth, Peter P ^e   Isermann, Berend ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; INFLAMMASOME; MINOCYCLINE; NFE2L2 PROTEIN, MOUSE; NLRP3 PROTEIN, MOUSE; TRANSCRIPTION FACTOR NRF2;

ANIMAL; DIABETIC NEPHROPATHY; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOLOGY; PROTEIN STABILITY;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; INFLAMMASOMES; MICE; MICE, KNOCKOUT; MINOCYCLINE; NF-E2-RELATED FACTOR 2; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; PROTEIN STABILITY;

EID: 84990996919     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep34228     Document Type: Article

References (64)

1. Martinez-Castelao, A., Navarro-Gonzalez, J. F., Gorriz, J. L. and de Alvaro, F. The Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent Years. J Clin Med 4, 1207-1216 (2015).
2. Reidy, K., Kang, H. M., Hostetter, T. and Susztak, K. Molecular mechanisms of diabetic kidney disease. J Clin Invest 124, 2333-2340 (2014).
3. Zoja, C., Zanchi, C. and Benigni, A. Key pathways in renal disease progression of experimental diabetes. Nephrol Dial Transplant 30 Suppl 4, iv54-iv59 (2015).
4. Forbes, J. M. and Cooper, M. E. Mechanisms of diabetic complications. Physiol Rev 93, 137-188 (2013).
5. Choi, B. H., Kang, K. S. and Kwak, M. K. Effect of redox modulating NRF2 activators on chronic kidney disease. Molecules 19, 12727-12759 (2014).
6. Ruiz, S., Pergola, P. E., Zager, R. A. and Vaziri, N. D. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int 83, 1029-1041 (2013).
7. Niture, S. K., Khatri, R. and Jaiswal, A. K. Regulation of Nrf2-an update. Free Radic Biol Med 66, 36-44 (2014).
8. Huang, X. S. et al. Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for hypoxic preconditioning-mediated delayed cardioprotection. Mol Cell Biochem 385, 33-41 (2014).
9. Suzuki, T., Motohashi, H. and Yamamoto, M. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci 34, 340-346 (2013).
10. Zheng, H. et al. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 60, 3055-3066 (2011).
11. Jiang, T. et al. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 59, 850-860 (2010).
12. Pergola, P. E. et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365, 327-336 (2011).
13. de Zeeuw, D. et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369, 2492-2503 (2013).
14. Kelly, K. J. et al. Minocycline inhibits apoptosis and inflammation in a rat model of ischemic renal injury. Am J Physiol Renal Physiol 287, F760-F766 (2004).
15. Sutton, T. A. et al. Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol 288, F91-F97 (2005).
16. Wang, J. et al. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem 279, 19948-19954 (2004).
17. Shah, A. P. et al. Effects of Minocycline on Urine Albumin, Interleukin-6, and Osteoprotegerin in Patients with Diabetic Nephropathy: A Randomized Controlled Pilot Trial. PLoS One 11, e0152357 (2016).
18. Isermann, B. et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 13, 1349-1358 (2007).
19. Kumar Bhatt, L. and Addepalli, V. Minocycline with aspirin: an approach to attenuate diabetic nephropathy in rats. Ren Fail 33, 72-78 (2011).
20. Susztak, K., Raff, A. C., Schiffer, M. and Bottinger, E. P. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55, 225-233 (2006).
21. Shahzad, K. et al. Caspase-1, but Not Caspase-3, Promotes Diabetic Nephropathy. J Am Soc Nephrol (2016).
22. Shahzad, K. et al. Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int 87, 74-84 (2015).
23. Alano, C. C., Kauppinen, T. M., Valls, A. V. and Swanson, R. A. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA 103, 9685-9690 (2006).
24. Ryan, M. E., Usman, A., Ramamurthy, N. S., Golub, L. M. and Greenwald, R. A. Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity. Curr Med Chem 8, 305-316 (2001).
25. Zhou, R., Yazdi, A. S., Menu, P. and Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221-225 (2011).
26. Ma, Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 53, 401-426 (2013).
27. Gao, C., Huang, W., Kanasaki, K. and Xu, Y. The role of ubiquitination and sumoylation in diabetic nephropathy. Biomed Res Int 2014, 160692 (2014).
28. Cukras, C. A., Petrou, P., Chew, E. Y., Meyerle, C. B. and Wong, W. T. Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study. Invest Ophthalmol Vis Sci 53, 3865-3874 (2012).
29. Syngle, A., Verma, I., Krishan, P., Garg, N. and Syngle, V. Minocycline improves peripheral and autonomic neuropathy in type 2 diabetes: MIND study. Neurol Sci 35, 1067-1073 (2014).
30. Zhou, R., Tardivel, A., Thorens, B., Choi, I. and Tschopp, J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11, 136-140 (2010).
31. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820 (2001).
32. Forbes, J. M., Coughlan, M. T. and Cooper, M. E. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57, 1446-1454 (2008).
33. Gao, L. and Mann, G. E. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc Res 82, 9-20 (2009).
34. Miki, H. and Funato, Y. Regulation of intracellular signalling through cysteine oxidation by reactive oxygen species. J Biochem 151, 255-261 (2012).
35. Perez-Matute, P., Zulet, M. A. and Martinez, J. A. Reactive species and diabetes: counteracting oxidative stress to improve health. Curr Opin Pharmacol 9, 771-779 (2009).
36. Anders, H. J. and Muruve, D. A. The inflammasomes in kidney disease. J Am Soc Nephrol 22, 1007-1018 (2011).
37. Balasubramaniam, G., Almond, M. and Dasgupta, B. Improved renal function in diabetic patients with acute gout treated with anakinra. Kidney Int 88, 195-196 (2015).
38. Jaiswal, A. K. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med 36, 1199-1207 (2004).
39. Wakabayashi, N., Slocum, S. L., Skoko, J. J., Shin, S. and Kensler, T. W. When NRF2 talks, whos listening? Antioxid Redox Signal 13, 1649-1663 (2010).
40. Sweetwyne, M. T. et al. Notch1 and Notch2 in Podocytes Play Differential Roles During Diabetic Nephropathy Development. Diabetes 64, 4099-4111 (2015).
41. Mooradian, A. D. Targeting Select Cellular Stress Pathways to Prevent Hyperglycemia-Related Complications: Shifting the Paradigm. Drugs 76, 1081-1091 (2016).
42. Tan, Y. et al. Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes 60, 625-633 (2011).
43. Velmurugan, G. V., Sundaresan, N. R., Gupta, M. P. and White, C. Defective Nrf2-dependent redox signalling contributes to microvascular dysfunction in type 2 diabetes. Cardiovasc Res 100, 143-150 (2013).
44. Foresti, R. et al. Nrf2 activators modulate oxidative stress responses and bioenergetic profiles of human retinal epithelial cells cultured in normal or high glucose conditions. Pharmacol Res 99, 296-307 (2015).
45. Chapple, S. J., Siow, R. C. and Mann, G. E. Crosstalk between Nrf2 and the proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging. Int J Biochem Cell Biol 44, 1315-1320 (2012).
46. Pergola, P. E. et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol 33, 469-476 (2011).
47. Garner, S. E. et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 8, CD002086 (2012).
48. Garrido-Mesa, N., Zarzuelo, A. and Galvez, J. Minocycline: far beyond an antibiotic. Br J Pharmacol 169, 337-352 (2013).
49. Lessem, J. and Hanlon, A. A post-marketing study of 2805 patients treated for periodontal disease with Arestin. J Int Acad Periodontol 6, 150-153 (2004).
50. Zoja, C. et al. Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am J Physiol Renal Physiol 304, F808-F819 (2013).
51. Alpers, C. E. and Hudkins, K. L. Mouse models of diabetic nephropathy. Curr Opin Nephrol Hypertens 20, 278-284 (2011).
52. Brosius, F. C. 3rd et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 20, 2503-2512 (2009).
53. Kosugi, T., Heinig, M., Nakayama, T., Matsuo, S. and Nakagawa, T. eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists. Am J Pathol 176, 619-629 (2010).
54. Nakagawa, T. et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 18, 539-550 (2007).
55. Niture, S. K., Jain, A. K., Shelton, P. M. and Jaiswal, A. K. Src subfamily kinases regulate nuclear export and degradation of transcription factor Nrf2 to switch off Nrf2-mediated antioxidant activation of cytoprotective gene expression. The Journal of biological chemistry 286, 28821-28832 (2011).
56. Meiners, S. et al. Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. Free Radic Biol Med 40, 2232-2241 (2006).
57. Luo, Z. F. et al. Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome. Life Sci 88, 512-520 (2011).
58. Sharma, K., McCue, P. and Dunn, S. R. Diabetic kidney disease in the db/db mouse. American journal of physiology. Renal physiology 284, F1138-F1144 (2003).
59. Bock, F. et al. Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proc Natl Acad Sci USA 110, 648-653 (2013).
60. Gil-Bernabe, P. et al. Exogenous activated protein C inhibits the progression of diabetic nephropathy. J Thromb Haemost 10, 337-346 (2012).
61. Shahzad, K. et al. Minocycline reduces plaque size in diet induced atherosclerosis via p27(Kip1). Atherosclerosis 219, 74-83 (2011).
62. Madhusudhan, T. et al. Defective podocyte insulin signalling through p85-XBP1 promotes ATF6-dependent maladaptive ER-stress response in diabetic nephropathy. Nat Commun 6, 6496 (2015).
63. Li, M. et al. Three-dimensional podocyte-endothelial cell co-cultures: Assembly, validation, and application to drug testing and intercellular signaling studies. Eur J Pharm Sci 86, 1-12 (2016).
64. Satchell, S. C., Anderson, K. L. and Mathieson, P. W. Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol 15, 566-574 (2004).